SR-91 is a natural killer (NK)-
Introduction
Natural killer (NK) cells, especially after they are activated by cytokines and become lymphokine activated killer (LAK) cells, contribute to the elimination and/or growth control of leukemic cells. [1] [2] [3] Both NK cells and LAK cells can kill a wide range of target cells without prior sensitization either through antibody-dependent cytotoxicity, (ADCC) via the Fc␥ receptor CD16, or through direct cell-mediated cytotoxicity. 4 Although the majority of leukemic cells are sensitive to cytolysis by LAK cells, 1 a small proportion appears to be resistant. 5, 6 It is conceivable that these resistant cells can escape NK/LAKmediated cytotoxicity and contribute to leukemic relapse. Since target cell lysis by NK/LAK cells generally involves a three-step process: (1) binding of target cells (conjugate formation); (2) activation of effector cells; and (3) release of cytotoxic molecules, including serine esterases and perforin, causing lysis of targets (effector phase), 4 leukemic cells may escape lysis by preventing any one of these three steps.
Cell adhesion molecules (CAMs) are critically involved in NK cell-mediated cytotoxicity. NK cells utilize CAMs to establish initial attachment to target cells. [7] [8] [9] They have also been implicated in the post-binding steps by providing stimulatory signals for the activation of effector cells. Among several CAMs involved in such interactions, LFA-1/ICAM-1 seems to constitute a dominant adhesion pathway for cytotoxic lymphocytes. 7, 10, 11 NK cytotoxicity can be effectively inhibited by mAb to either of these CAMs. More recently, NK cells from LFA-1-deficient mice were found to be unable to kill target cells, 12 further indicating the involvement of these CAMs in NK cytotoxicity.
The objective of this study was to gain some insight into the mechanisms by which some leukemic cells are resistant to NK/LAK cytotoxicity and test modalities that might enhance sensitivity of these cells to LAK cell-mediated lysis. We particularly focused on CAMs that may play a crucial role in conjugate formation between NK and target cells as well as in activation of NK cells following conjugate formation. For these studies, the NK/LAK-resistant leukemic cell line SR-91 and the human NK cell line NK-92 were used. NK-92 is a highly cytotoxic NK cell line established from a patient with malignant lymphoma. 13 It requires the presence of IL-2 for continuous growth and is similar to LAK cells with respect to surface receptor expression and functional abilities. 13 However, the cytolytic activity of NK-92 is much higher than that of primary LAK cells.
14 Furthermore, NK-92 lacks CD16 and does not display antibody-dependent cell-mediated cytotoxic (ADCC) activity. NK-92 is highly effective and kills virtually all leukemic cell lines so far tested with the exception of SR-91. This line was established from a patient with undifferentiated acute leukemia. It is resistant to both peripheral bloodderived NK/LAK cells 15 and NK-92. Studies presented here reveal that conjugate formation between SR-91 and NK-92 is increased by treatment of SR-91 cells with tumor necrosis factor-alpha (TNF-␣) or interferon-␥ (IFN-␥), both of which induce expression of ICAM-1. However, conjugate formation alone is not sufficient for NK-92 cell-mediated cytolysis of SR-91 since TNF-␣, but not IFN-␥ makes SR-91 sensitive to NK/LAK cells. On the other hand, TNF-␣ but not IFN-␥, activates LFA-1 and CD44 on SR-91 cells. These CAMs may bind to their counter receptors, ICAMs and CD44 respectively, on NK-92 cells and activate them, suggesting a role for these CAMs as activation receptors on NK-92.
Materials and methods

Cells and culture medium
K562 (erythroleukemia) and Daudi (Burkitt lymphoma) cell lines were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). SR-91 and NK-92 cell lines were established in our laboratory and their characteristics have been described previously. 13, 15 K562, Daudi and SR-91 cells were maintained in continuous suspension culture in RPMI 1640 supplemented with 10% fetal calf serum (FCS), penicillin at 10 −6 units/ml and streptomycin at 100 g/ml. NK-92 cells were maintained in myeloid long-term culture medium (Myelocult; StemCell Technologies, Vancouver, BC, Canada) supplemented with 200 units/ml recombinant IL-2 (provided by Amgen Canada, Mississauga, ON, Canada).
Antibodies and reagents
The following murine monoclonal antibodies to human antigens were used: affinity purified antibodies to CD54 (anti-ICAM-1, clone RR1. 1 
Flow cytometry
Expression of adhesion receptors on SR-91 cells was examined by indirect immunofluorescence with appropriate isotype-matched antibodies used for control experiments. For each sample, 5000 events were collected on a FACScan (Becton Dickinson, Mountain View, CA, USA) and analyzed using Hewlett Packard HP340 software.
Cytotoxicity assay
NK cytotoxicity test was performed in a 4 h 51 Cr release assay as previously described. 17 Antibody inhibition experiments were performed using antibodies against LFA-1, ICAM-1, ICAM-2 and ICAM-3. Different antibodies were either preincubated with effector or target cells for 30 min at 25°C and the excess antibody was removed by two washes prior to the cytotoxicity assay, or antibodies were added to the reaction mixture and were present during the cytotoxicity assay.
Conjugate formation assay
To quantitate the binding between SR-91 and NK-92 cells, a conjugate formation assay was performed as previously described. 18, 19 Briefly, effector and target cells were washed separately in serum-free phosphate-buffered saline (PBS), resuspended at two times the desired concentration in 500 l and mixed with an equal volume of 1-2 g/ml of fluorescent cell linkers PKH26 (red fluorescence) and PKH2 (green fluorescence) (Sigma), respectively. The cells were incubated in the dark for 2-5 min at 25°C. The staining reaction was stopped by adding an equal volume of FCS and incubating at 25°C for 1 min. After adding 2 ml RPMI/FCS 10%, cells were centrifuged at 400 g for 10 min, the supernatant removed and the pellet resuspended in Hank's balanced salt solution (HBSS) containing 2% FCS, transferred into a new tube and washed three times with HBSS/FCS 10%. The cell pellets were then resuspended at the desired concentration in PBS containing 5 mM MgCl 2 and 1 mM EGTA. To allow for conjugate formation, 100 l aliquots of effector and target cells were mixed, centrifuged at 400 g for 3 min, incubated for 10 min at 37°C and then analyzed by flow cytometry. To eliminate non-specific conjugate formation, two-color labeled effector/effector and target/target cells were also examined. A total of 5000 events were collected. The percentage of conjugated cells was determined by dividing the number of dual labeled particles by the total number of cells bearing that label.
Adhesion assay
To determine the activation state of LFA-1, CD44 and the ␤1 integrins, adhesion assays using fluorescent tagged SR-91 cells were performed essentially as described. 20 Briefly, 96-well flat bottom plates (Falcon; Becton Dickinson, Franklin Lakes, NJ, USA) were coated with soluble ICAM-3 (sICAM-3, 4 g/ml in TSM buffer (25 mM Tris-HCl, pH 8.2, 150 mM NaCl, 2 mM MgCl 2 ) ) for 2 h at 37°C (to measure the activation state of LFA-1), or with fibronectin (1 mg/ml in PBS) (for the ␤1 integrins) overnight at 4°C. 24-Well plates (Falcon) were coated overnight at 4°C with hyaluronan (Sigma) (5 mg/ml in PBS) to assess CD44 activation. As a control, 0.1% bovine serum albumin (BSA) was coated to the same plates. At the end of the incubation time, wells were washed twice with PBS prewarmed to 37°C, and saturated with PBS containing 0.1% BSA for 30 min at 37°C.
For fluorescent labeling, SR-91 cells were washed three times with serum-free HBSS, resuspended in 1 ml serum-free HBSS and 1-5 g/ml calcein AM (Molecular Probes, Eugene, OR, USA) added to the cell suspension. After incubation at 37°C for 45 min, cells were washed once in HBSS and once with HBSS/FCS 2% and resuspended in HBSS/FCS 2%. For binding, 500 l or 50 l of the cell suspension (1 × 10 6 cells/ml) were added to the 24-or 96-well plates, respectively, and incubated for 30 min at 37°C. Non-adherent cells were gently removed, the plates gently washed twice with prewarmed PBS and the wells overlaid with PBS. The intensity of the fluorescence bound to the wells was determined using a fluorescent plate reader (Bio-Instruments, Highland Park, VT, USA; model EL30q). The percentage of bound cells was determined by referring to a standard curve established using known numbers of fluorescent cells.
DNA fragmentation assay
Cells were incubated overnight with different doses of TNF-␣. 1 × 10 6 Cells were used for each condition. Cells were washed in PBS, pelleted and DNA obtained by lysing the cell pellet in 20 l of apoptosis lysis buffer (0.1% Na Citrate, 0.1% Triton X-100, pH 8). DNA samples were incubated for 1 h at 50°C, after addition of 1 l of 10 mg/ml proteinase K, and further incubated for 1 h at 50°C in the presence of 10 l of 1 g/ml RNase. Samples were then incubated at 70°C for 10 min, and after the addition of 10 l of loading buffer, loaded in 1% agarose gel containing 0.1 mg/ml ethidium bromide, and run at 90 volts.
Results
SR-91 cells are NK/LAK resistant
SR-91 is a leukemia cell line derived from a patient with undifferentiated acute leukemia. 15 It is resistant to both peripheral blood-derived NK/LAK cells and NK-92 cells (Figure 1 ). NK-92 is a highly cytotoxic NK cell line and kills all leukemic cell lines so far tested 13, 14 with the only exception being SR-91. As can be seen in Figure 1b , lysis of SR-91 cells by NK-92 cells, even at an effector:target (E:T) cell ratio of 50:1, was consistently less than 15%. In contrast, NK-92 kills K562 and Daudi cells very effectively (60-80% cytotoxicity at an effector:target ratio of 1:1).
TNF-␣ and IFN-␥ treatment increases ICAM-1 expression on SR-91 and enhances conjugate formation between SR-91 and NK-92 cells
Flow cytometric analysis of SR-91 cells showed that they express very low levels of ICAM-1 (mean fluorescence channel of 8) (Figure 2 ). Because cell adhesion mediated by LFA-1 on NK cells and ICAM-1 on target cells is thought to be crucial for NK cytotoxicity, we postulated that the low level of ICAM-1 expression may be responsible for the resistance of SR-91 to NK/LAK cell cytotoxicity. To test this, SR-91 cells were treated with either 500 U/ml of TNF-␣ or IFN-␥ two cytokines known to upregulate ICAM-1 expression. ICAM-1 expression on SR-91 was significantly increased by these two cytokines, and to approximately the same degree (mean fluorescence channel of 130 for TNF-␣, 100 for IFN-␥) ( Figure  2 ). In contrast, the other members of this adhesion receptor family (ICAM-2 and ICAM-3) or LFA-1 were constitutively expressed on SR-91 cells and were not significantly increased by cytokine treatment (Figure 2) .
To determine if the upregulation of ICAM-1 on SR-91 cells with cytokine treatment had functional significance, we first examined its effect on conjugate formation between SR-91 and NK-92 cells. SR-91 and NK-92 were labeled with two distinct fluorescent dyes and a conjugate formation assay performed. Effector-target cell conjugates were visualized by (Figure 3) . Antibody against ICAM-1 alone did not significantly affect conjugate formation. These results indicate that ICAM-1 expression is required for efficient conjugate formation but ICAM-2 and -3 are also involved.
TNF-␣ but not IFN-␥, enhances sensitivity of SR-91 to NK cells
TNF-␣ treatment significantly increased the sensitivity of SR-91 to both NK-92 ( Figure 4 ) and primary NK/LAK cells isolated from peripheral blood (data not shown). In contrast, IFN-␥ even at 500 U/ml, did not increase the sensitivity of SR-91 cells to NK cell-mediated cytotoxicity. To determine the contribution of CAMs to cytotoxicity in this system, the effects of mAbs to LFA-1 and ICAMs were examined. Similar to what was observed for inhibition of conjugate formation, NK-92 cell-mediated cytotoxicity was almost completely inhibited by anti-LFA-1 whereas anti-ICAM-1 only partially inhibited it. A combination of mAbs to ICAM-2 and -3 had no effect. To achieve the level of inhibition comparable to that achieved by anti-LFA-1, a combination of mAbs against all three ICAMs was required ( Figure 5 ).
TNF-␣ does not induce apoptosis in SR-91 cells
TNF-␣ is known to induce DNA fragmentation in some cells either directly or through induction of other apoptotic pathways such as the Fas-Fas ligand pathway. 21 To determine whether TNF-␣ was actually inducing apoptosis of SR-91 cells in the absence of NK-92 cells, DNA was isolated from SR-91 cells treated overnight with different doses of TNF-␣ and 
Figure 3
Quantification of effector-target conjugate formation by dual-color flow cytometry, and inhibitory effect of antibodies on conjugate formation. After incubating SR-91 cells with TNF-␣ or IFN-␥ at 500 U/ml for 16 h, effector and target cells were labeled with two different fluorescent dyes (red and green fluorescence respectively), and a conjugate formation assay was performed as described in Materials and methods, in the presence or absence of antibodies to LFA-1 and the different ICAMs. Effector-target conjugates were visualized by flow cytometry as double-color events. The percentage of conjugates was obtained by dividing the number of dual labeled particles by the number of target cells multiplied by 100. Anti-LFA-1 mAb was used at 1:20 dilution of hybridoma supernatant, affinity purified monoclonal antibodies anti-ICAM-1, anti-ICAM-2 and anti-ICAM-3 were used at 5-10 g/ml. The percentage of effector-target conjugates is stated in the heading of each plot. One representative experiment (out of three independent experiments) is shown. analyzed by agarose gel electrophoresis. HL-60 and U937 cells were used as positive controls for TNF-␣-induced apoptosis. We found that TNF-␣ did not induce DNA fragmentation of SR-91 cells, whereas apoptosis of HL-60 and U937 was readily detected by this assay (Figure 6 ). To determine whether Fas-Fas ligand-mediated apoptosis was induced by TNF-␣ cytotoxicity assays were also performed in the presence and absence of calcium. Our results clearly demonstrated that the lysis of TNF-␣-treated SR-91 by NK-92 is totally dependent on calcium (data not shown). Therefore, the
Figure 5
Effect of different antibodies on the cytotoxicity of NK-92 against TNF-␣ treated SR-91. Target cells were incubated with TNF-␣ at 500 U/ml for 16 h, and a
51
Cr release assay performed after antibodies against different adhesion molecules were added to the cells (as described in the legend to Figure 3) . (a) Shows the mean of five independent experiments ± s.d; one representative experiment (out of three independent experiments) is shown in (b).
Fas-Fas ligand pathway, which is calcium independent, 22 does not seem to be involved in this cytotoxicity.
TNF-␣ but not IFN-␥ activates LFA-1, CD44 and ␤1 integrins on SR-91 cells
The above results demonstrated that both TNF-␣ and IFN-␥ upregulate ICAM-1 expression on SR-91 cells, but only TNF-␣ makes SR-91 cells sensitive to NK-mediated killing. It was therefore hypothesized that TNF-␣ not only induces ICAM-1 expression but also activates other molecules on the surface of SR-91 cells that interact with their counter-receptors on NK-92 cells and activate them. To test this, the activation state of LFA-1, CD44 and ␤1 integrins was determined by binding of SR-91 cells to plastic wells coated with sICAM-3, hyaluronan and fibronectin, respectively. TNF-␣-treated, but not untreated or IFN-␥-treated SR-91 cells, showed increased binding to sICAM-3, hyaluronan and fibronectin (Figures 7 and 8) . PMA was used as a positive control for the activation of LFA-1 and ␤1 integrins. In addition, TNF-␣-treated SR-91 cells also expressed the CD44 activation epitope, 7F4, while IFN-␥-treated cells did not (Figure 8 ). These results indicate that TNF-␣, but not IFN-␥ functionally activates LFA-1, CD44 and fibronectin receptors.
Discussion
The leukemic line SR-91 used in this study is highly resistant to NK/LAK cell cytotoxicity. Our results, using the human NK cell line NK-92, indicate that at least two mechanisms are involved in this NK resistance. First, due to the very low level of ICAM-1 expression on SR-91, NK cells fail to efficiently form conjugates with SR-91 cells. Because physical binding of NK cells to their targets is thought to be a prerequisite for killing of target cells, this lack of ICAM-1 expression is likely important for NK resistance of SR-91 cells. Second, although both TNF-␣ and IFN-␥ increased ICAM-1 expression on SR-91 and conjugate formation between NK-92 and SR-91 to similar levels, only TNF-␣ was able to render the target SR-91 cells sensitive to NK cell killing. This TNF-␣ action was not through
Figure 6
DNA fragmentation assay. SR-91 and TNF-␣-sensitive cell lines HL-60 and U937 cells were exposed to various doses of TNF-␣ (0, 500, 1000 and 2000 U/ml), for 16 h. DNA was extracted and resolved by agarose gel electrophoresis as described in Material and methods. 1 × 10 6 Cells were analyzed in each experiment.
Figure 7
Activation of LFA-1 and ␤1 integrins on SR-91. SR-91 cells were incubated for 16 h with TNF-␣ or IFN-␥ and tested for their binding to plastic wells coated with soluble ICAM-3 and fibronectin, respectively, either in the absence or presence of PMA (added at 100 ng/ml during the adhesion assay). The percentage of bound cells was determined by referring to a standard curve established using a series of known number of fluorescent cells.
Figure 8
Activation of CD44 on SR-91 cells and TNF-␣ treated cells. Untreated and cytokine-treated SR-91 cells were analyzed (a) by flow cytometry for the expression of the activation epitope of CD44, 7F4 and (b) in adhesion assay with hyaluronan coated wells (as described in the legend to Figure 7) . induction of apoptosis either directly on target cells or via induction of the Fas pathway. Interestingly, the increased binding induced by both cytokines and the TNF-␣-induced sensitivity of SR-91 cells to NK-92 cell killing were abrogated by anti-LFA-1 mAb as well as a combination of antibodies against the three ligands of LFA-1, ICAM-1, ICAM-2 and ICAM-3, while anti-ICAM-1 on its own had only a partial effect. This demonstrates the essential contribution of the LFA-1 and all three ICAMs to the initial binding of NK cells to target cells.
Since our studies showed that enhanced conjugate formation was insufficient to overcome resistance to NK cell killing, we hypothesized that TNF-␣ may cause the activation of other molecules on SR-91 cells that, upon binding to their counterreceptors on NK-92 cells, lead to their activation. TNF-␣ but not IFN-␥ treatment of SR-91 induced activation of, CD44, LFA-1 and ␤1 integrins. Although the roles of these CAMs in NK cytotoxicity have been extensively studied, relatively little is known about the importance of these CAMs expressed on target cells.
CD44 has been implicated in signal transduction events and the triggering of cytotoxic functions of CTL [23] [24] [25] and NK cells. [26] [27] [28] It has also recently been reported to associate with the protein tyrosine kinase p56 lck in T cells. 29 Although CD44 functions as a receptor for the glycosaminoglycan hyaluronan, there is increasing evidence that binding to hyaluronan cannot explain all CD44-dependent adhesion events. It has recently been demonstrated that alternatively spliced CD44 isoforms containing exon V10 (eg CD44R1) can be recognized and bound by other CD44 molecules thereby promoting cell-cell interactions. 16 SR-91 expresses CD44H, and TNF-␣ treatment upregulates CD44R1 expression. Importantly, TNF-␣ also induces the expression on CD44 molecules of an epitope recognized by mAb 7F4. Reactivity with this antibody is increased on peripheral blood T cells following PHA stimulation, an event that parallels acquisition of the capacity to bind hyaluronan. Analysis of a large panel of lymphoid and myeloid cell lines has confirmed a direct correlation between 7F4 expression and hyaluronan binding ability, suggesting that it defines an activation epitope associated with functional activation of the CD44 molecule. 16 NK-92 cells express both CD44H and CD44R1 as well as the activation epitope defined by mAb 7F4, presumably as a consequence of activation by IL-2. Our results demonstrate activation of CD44 on SR-91 cells by TNF-␣ treatment. Although they do not prove a causal relationship between this activation and the induction of sensitivity to NK-mediated killing, it is conceivable that the activation of CD44 (H and R1) on SR-91 cells by TNF-␣, allows interaction with funcionally active CD44R1 or CD44H on NK-92 cells, thereby providing costimulatory signals to the effector population. Further studies will be aimed at delineating whether overexpression or activation of CD44 on the target cell can contribute to an increased target sensitivity to NK cell-mediated lysis.
LFA-1 on SR-91, upon activation with TNF-␣, may bind its counter-receptors on NK-92 cells. ICAM-3, unlike ICAM-1 and ICAM-2, has a longer cytoplasmic domain that contains an immunoreceptor tyrosine-based activation motif (ITAM), which is believed to play a role in receptor function. [30] [31] [32] [33] [34] Therefore, ICAM-3 may play a more dominant role in signal transduction than ICAM-1 or ICAM-2. ICAM-3 has been shown to be costimulatory for both resting and activated T lymphocytes. 35 More recently, ICAM-3, which has no intrinsic kinase activity, has been reported to associate with Src family protein tyrosine kinases lck and fyn in Jurkat T cells. 36 It is possible that LFA-1 on TNF-␣-treated SR-91 binds to ICAM-3 on NK-92 and activates the latter. Although the involvement of LFA-1 on NK cells in cytotoxicity has been well established, our studies suggest that LFA-1 on leukemic cells and its activation state may also play a role.
The data presented here demonstrate that ICAM-1 expression on the target cell SR-91 is essential for conjugate formation between effector and target cells. However, this in itself is insufficient to allow target cell lysis by NK-92 cells. ICAM-2 and ICAM-3 on SR-91 cells also participate in effector-target binding but their effect is clearly less important. The differential effects of TNF-␣ and IFN-␥ on SR-91 with regard to both activation state of LFA-1 and CD44, and the induction of sensitivity to NK-mediated killing suggests that this may involve CAMs on NK-92 cells other than LFA-1. Among several CAMs known to be expressed on NK cells, ICAM-3 and CD44 are of particular interest. They have been reported to be costimulatory for T lymphocytes (ICAM-3) and to trigger cytotoxic functions of both CTL and NK cells (CD44). There In conclusion, these results demonstrate that the NK-resistant leukemic line SR-91 becomes NK sensitive by TNF-␣ treatment. Our results suggest that activation of LFA-1 and CD44 on SR-91 cells may be involved in this process. This effect of TNF-␣, which has not been described previously, may have important implications with respect to the treatment of leukemia. NK/LAK cells have proven to be effective in the treatment of hematological malignancies. 1, 2, 3, 7 One of the problems associated with the use of NK/LAK cells for the treatment of leukemia is that some leukemic cells are resistant to their cytotoxic effects. This research was undertaken to investigate underlying causes of this resistance, and to determine if an improvement of this therapeutic modality could be achieved by modulating the expression of CAMs. Our results suggest that at least some NK/LAK-resistant leukemic cells can become sensitive with appropriate treatment. It will be of interest to assess if this observation can be confirmed for other leukemic cells and particularly if it can be extended to fresh leukemic cells. This could improve the outcome of approaches using NK cells in the treatment of leukemia.
